Abstract:Abstract Pancreatic ductal adenocarcinoma (PDA) is a particularly lethal malignancy that lacks effective therapeutic strategies. A promising therapeutic modality that can elicit transient antitumor responses in a subset of metastatic PDAs is chemotherapy + CD40 agonist +/- anti-PD-1. A deeper understanding of the cellular mechanisms that mediate the initial responses will inform new strategies to enhance the durability of this therapy. Our prior studies demonstrated that tumor-specific CD4 T cells are critical for mitigating tumor growth in a syngeneic KPC orthotopic tumor model of PDA that expresses a model neoantigen, click beetle red luciferase (CBR). CD4 T cells direct tumor antigen recognition by tumor-associated macrophages and host interferon-gamma receptor (Ifngr1) signaling. Here, we demonstrate that CD4 T cells are required for the antitumor effects of anti-CD40 agonist indicating that this therapy fails to compensate for a lack of CD4 T cell help. We sought to test the hypothesis that host Ifngr1 signaling acts in a CD4 T cell intrinsic manner to promote antitumor responses. As such, we develop and validate a novel MHC class II tetramer (CBR54-62:I-Ab) to track the fate of endogenous CD4 T cells during tumor growth. We demonstrate that tumor-specific CD4 T cell abundance and Th1 polarization is decreased in orthotopic tumors, particularly between day 14 and day 21 post tumor implantation. Combination agonistic anti-CD40 + anti-PD-L1 maintained tumor-specific CD4 T cell numbers in the spleen and pancreas-draining lymph nodes of tumor-bearing mice. Intriguingly, Th1 polarized tumor-infiltrating CD4 T cells were decreased by aPD-L1, but were restored by anti-CD40, a finding further corroborated by single-cell RNA sequencing. Further, agonistic anti-CD40 + anti-PD-L1 alone or in combination robustly decreased Treg polarized tumor-specific CD4 T cells. Using a mixed bone marrow chimeric approach, we show immunotherapy’s Treg-depletion effect is dependent on Ifngr1 on antigen-specific CD4 T cells. In contrast, Ifngr1 signaling on tumor-specific CD8 T cells appeared inconsequential to CD8 T cell fate following immunotherapy. To our knowledge, this is the first study to interrogate tumor-specific CD4 T cells in PDA and uncover novel interplay between CD4 T cells, CD8 T cells, and myeloid cells that are critical for immunotherapy response. Citation Format: Eduardo Cruz-Hinojoza, Adam Burrack, Zoe Schmiechen, Cara-Lin Lonetree, Ebony A. Miller, Michael Patterson, Jesse Williams, Thamotharampillai Dileepan, Ingunn Stromnes. Ifngr1 signaling on tumor-specific CD4 T cells is required to mitigate Treg differentiation during CD40 agonist and anti-PD-L1 immunotherapy in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5308.

Global pannexin 1 deletion increases tumor‐infiltrating lymphocytes in the BRAF/Pten mouse melanoma model

Pannexin 1 binds β-catenin to modulate melanoma cell growth and metabolism

Pannexin 1 crosstalk with the Hippo pathway in malignant melanoma

Novel Pannexin 1 isoform is increased in cancer

Propionyl-CoA carboxylase subunit B regulates anti-tumor T cells in a pancreatic cancer mouse model

A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma

Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma

PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy

Pannexin 1 and Pannexin 3 differentially regulate the tumorigenic properties of cutaneous squamous cell carcinoma

PANoptosis‐related signature in melanoma: Transcriptomic mapping and clinical prognostication

CAF Specific Expression of Podoplanin May Be Dispensable for the Malignancy of Malignant Melanoma

Pancancer transcriptomic profiling identifies key PANoptosis markers as therapeutic targets for oncology

Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy

Panx1 Promotes Invasion-Metastasis Cascade in Hepatocellular Carcinoma

Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

Genetic Aberrations in the CDK4 Pathway and Association with Innate Resistance to PD-1 Blockade in Acral Melanoma.

Abstract 5308: Ifngr1 signaling on tumor-specific CD4 T cells is required to mitigate Treg differentiation during CD40 agonist and anti-PD-L1 immunotherapy in pancreatic ductal adenocarcinoma

B cell c-Maf signaling promotes tumor progression in animal models of pancreatic cancer and melanoma

Tumor-associated nonmyelinating Schwann cell–expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion

Patient Derived Xenografts Demonstrate the Radiosensitizing Effect of Inhibiting MAPK Signaling Pathway in Pancreatic Ductal Adenocarcinoma